Chronic kidney disease is defined as decreased glomerular filtration rate (GFR) less than 60ml/min/1.73m² for three months or more. The best available therapeutic option for the patient’s long-term survival is renal transplantation. Renal transplantation is associated with moderate to severe postoperative pain requiring effective pain management. Perioperative 2% lignocaine infusion has been used for post operative pain relief, however very little evidence is available for its use in renal transplant patients.

The study aims to evaluate the impact of 2% lignocaine infusion on reducing fentanyl consumption in this patient population in the postoperative period. By reducing opioid consumption, lignocaine infusion may provide a useful adjunct to standard anaesthesia and pain management, leading to improved patient outcomes.

In this double-blind randomized trial, we will enrol 50 patients, 25 patients in two groups scheduled for elective renal transplant surgery. Participants will be randomly assigned into two groups: Group A will be receiving 2% lignocaine 1.5mg/kg bolus dose at induction followed by infusion 1.5mg/kg/hr till renal reperfusion, Group B will be receiving normal saline at the same rate and same volume in patient undergoing renal transplant surgery. Post- surgery, patients will receive patient-controlled analgesia (PCA) with fentanyl and cumulative fentanyl consumption will be recorded within 24 hours period.

This study hypothesizes that 2% lignocaine infusion will decrease fentanyl consumption by 30%, post operatively in renal transplant recipients.